Liege, Belgium, 22 October 2019 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of abstracts on Estelle® clinical results presented at the 13th Annual Meeting of the European Society of Gynecology (ESG) held from 16-19 October 2019 in Vienna, Austria.
Mithra today announces that its Phase III results for Estelle® will be presented at the 13th Annual Meeting of the European Society of Gynecology (ESG) taking place from 16-19 October 2019 in Vienna, Austria.
Mithra grants an exclusive license for commercialization of vaginal contraceptive ring in China The introduction of a long acting contraceptive method represents a compelling new alternative for women in China Liege, Belgium, 14 October 2019, 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into […]
Recruitment of the first patient marking the launch of “E4 Comfort” Phase III Clinical Program for Donesta® in menopausal women with vasomotor symptoms Phase III program includes two pivotal studies aimed at enrolling a total of 2200 women aged from 40 to 65 years Liege, Belgium, 9 October 2019 – 7:30 CEST – Mithra (Euronext Brussels: […]
Liege, Belgium, 3 October 2019 – 7 :30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today provides supplementary details related to the US deal with Mayne Pharma for Estelle®.
Remaining payment obligations to Uteron Pharma reduced by 62% to EUR 250 million otal payment duration reduced by twelve years Substantial reduction of total debt under IFRS Significant cash flow improvement safeguarding the development of Estelle® and Donesta® Option for Mithra to pay EUR 40 million cash tranche in equity Liege, Belgium, 1 October 2019 […]
Historical agreement with Mayne Pharma, who became the second largest supplier of oral contraceptives in the US after the acquisition of a portfolio of branded generic products from TEVA in 2016 Record deal value for Estelle®. Potential gross revenues in Mithra’s worst-case scenario at a minimum of EUR 4,5 billion, which represents more than twice […]
Strong revenue growth from continuing operations (+191%) with best first half-year EBITDA since IPO Cash position remains solid at EUR 77.5 million, key for further R&D development Confirmed unique safety profile of Mithra’s innovative contraceptive pill Estelle® following positive results in both Europe/Russia and United States/Canada. Filing with regulatory authorities planned by end of 2019 […]
Mithra grants exclusive license to Dexcel Pharma for commercialization of its two leading contraceptive products in Israel Dexcel Pharma is Israel’s largest private pharmaceutical company Production at the Mithra CDMO facility in Belgium Liege, Belgium, 20 August 2019 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it […]
Estelle®, Mithra’s oral contraceptive product candidate, has been granted a key patent for the dysmenorrhea indication in Japan, a four times larger market than the contraceptive one. Important milestone for the commercialization of Estelle® by Fuji Pharma in Japan and ASEAN, representing a total attractively priced market of EUR 400 million annual sales. Thanks to a solid […]